EUVIMEDEUVIMED entdecken
Crossref

Cost-effectiveness analysis of pembrolizumab in patients with treatment-refractory metastatic colorectal cancer in Japan

Kiyoaki Sugiura iD, Hiroki Hiratsuka, Go Oshima, Satoshi Aiko

Japanese Journal of Clinical Oncology · 2023

DOI: 10.1093/jjco/hyad050 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Japanese Journal of Clinical Oncology, 2023. Verfasst von Kiyoaki Sugiura und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Eiju General Hospital, Tokyo, Japan. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Rectal Neoplasms, Colonic Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The immune checkpoint inhibitor pembrolizumab has recently been recognized as a standard treatment regimen for patients with metastatic colorectal cancer and the microsatellite-instability-high/mismatch repair-deficient mutation. However, its cost-effectiveness in late-line treatment remains unclear. The aim of this study was to assess the cost-effectiveness of pembrolizumab for patients with microsatellite-instability-high/mismatch repair-deficient metastatic colorectal cancer.

Methods

Markov decision modeling using treatment costs, disease-free survival and overall survival was performed to examine the cost-effectiveness of pembrolizumab monotherapy compared with chemotherapy, and best supportive care. The Japanese healthcare payer’s perspective was adopted. The outcomes were modeled on the basis of published literature. The primary outcome was the incremental cost-effectiveness ratio between the strategies. Sensitivity analyses were performed and the effects of uncertainty on the model parameters were investigated.

Results

Pembrolizumab monotherapy had incremental cost-effectiveness ratios of $408204.3 per quality-adjusted life-year gained compared with best supportive care and $489123.4 per quality-adjusted life-year gained compared with chemotherapy. Given a Japanese willingness-to-pay threshold of $69560.38 per quality-adjusted life-year, the base case results suggested that pembrolizumab monotherapy was not cost-effective. The sensitivity analysis results were in line with the base case results.

Conclusion

Pembrolizumab monotherapy is not a cost-effective option in late-line treatment for patients with metastatic colorectal cancer and microsatellite-instability-high/mismatch repair-deficient mutation in the Japanese healthcare system. Further studies on its cost-effectiveness in first-line treatment are warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsRectal NeoplasmsColonic NeoplasmsQuality-Adjusted Life YearsCost-Benefit AnalysisAntineoplastic Combined Chemotherapy ProtocolsJapanHumansCost-Effectiveness AnalysisAntibodies, Monoclonal, HumanizedBrain NeoplasmsNeoplastic Syndromes, Hereditary

Stichwörter der Autor:innen

colorectal neoplasmscost-effectiveness analysisimmune checkpoint inhibitors

Substanzen

pembrolizumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Surgery, Eiju General Hospital, Tokyo, Japan.

ORCID-Profile: Kiyoaki Sugiura

Zitieren

APA

Sugiura, K., Hiratsuka, H., Oshima, G., & Aiko, S. (2023). Cost-effectiveness analysis of pembrolizumab in patients with treatment-refractory metastatic colorectal cancer in Japan. Japanese Journal of Clinical Oncology. https://doi.org/10.1093/jjco/hyad050

Vancouver

Sugiura K, Hiratsuka H, Oshima G, Aiko S. Cost-effectiveness analysis of pembrolizumab in patients with treatment-refractory metastatic colorectal cancer in Japan. Japanese Journal of Clinical Oncology. 2023. doi:10.1093/jjco/hyad050

BibTeX
@article{Sugiura2023,
  author = {Sugiura, Kiyoaki and Hiratsuka, Hiroki and Oshima, Go and Aiko, Satoshi},
  title = {Cost-effectiveness analysis of pembrolizumab in patients with treatment-refractory metastatic colorectal cancer in Japan},
  journal = {Japanese Journal of Clinical Oncology},
  year = {2023},
  doi = {10.1093/jjco/hyad050}
}
Kostenlos starten →